Immunotherapy in Esophagogastric Adenocarcinoma

被引：3
|
作者：
Stein, Alexander [1 ]
Thuss-Patience, Peter [2 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
来源：
VISCERAL MEDICINE | 2019年 / 35卷 / 01期
关键词：
Immunotherapy; Esophagogastric adenocarcinoma; Combination; Chemotherapy; Targeted therapy; GASTROESOPHAGEAL JUNCTION CANCER; DOUBLE-BLIND; CHEMOTHERAPY; PEMBROLIZUMAB; MONOTHERAPY; NIVOLUMAB; EFFICACY; SAFETY;
D O I：
10.1159/000497292
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Immunotherapy, particular PD-1/L1 inhibition, is a relevant treatment approach in esophagogastric adenocarcinoma. To date, single-agent activity is limited to the chemotherapy refractory setting and molecularly defined subgroups. Currently, ongoing trials, which are likely to relevantly change the landscape of treatment for this disease in the next years, evaluate different combination approaches with chemotherapy and/or molecular targeted agents in different disease settings. The German AIO study group has launched several combination trials in the perioperative, first-line, and advanced disease setting to further define the role of immunotherapy in esophagogastric adenocarcinoma. (C) 2019 S. Karger AG, Basel
引用
收藏
页码：12 / 16
页数：5
相关论文
共 50 条
  • [31] Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
    Landi, Lorenza
    D'Inca, Federica
    Gelibter, Alain
    Chiari, Rita
    Grossi, Francesco
    Delmonte, Angelo
    Passaro, Antonio
    Signorelli, Diego
    Gelsomino, Francesco
    Galetta, Domenico
    Giannarelli, Diana
    Parra, Hector Soto
    Minuti, Gabriele
    Tiseo, Marcello
    Migliorino, Maria Rita
    Cognetti, Francesco
    Toschi, Luca
    Bidoli, Paolo
    Piantedosi, Francovito
    Calabro, Luana
    Cappuzzo, Federico
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [32] New Immunotherapy and Lung Cancer
    de Cos Escuin, Julio Sanchez
    ARCHIVOS DE BRONCONEUMOLOGIA, 2017, 53 (12): : 682 - 687
  • [33] Cancer immunology and melanoma immunotherapy
    Marques Linck, Rudinei Diogo
    de Paula Costa, Romulo Leopoldo
    Garicochea, Bernardo
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2017, 92 (06) : 830 - 835
  • [34] Immunotherapy in Older Adults with Cancer
    Godby, Richard Curtis
    Johnson, Douglas B.
    Williams, Grant R.
    CURRENT ONCOLOGY REPORTS, 2019, 21 (07)
  • [35] Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma
    Li, Peng
    Che, Shuyu
    Qi, Yingxue
    Luo, Ningning
    Lin, Qiuju
    Zhu, Xiaofeng
    Xuan, Yunpeng
    Li, Mengmeng
    Li, Jinlong
    Ge, Minghui
    Sun, Tingting
    Qi, Chuang
    Wang, Yongjie
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 2997 - 3007
  • [36] Perioperative treatment of adenocarcinoma of the esophagus and esophagogastric junction
    Knoedler, M.
    Kuhnt, T.
    Lordick, F.
    ONKOLOGE, 2014, 20 (12): : 1210 - +
  • [37] Multimodal treatment of adenocarcinoma of the esophagus and esophagogastric junction
    Stahl, M.
    ONKOLOGE, 2010, 16 (05): : 504 - 509
  • [38] Perioperative treatment of adenocarcinoma of the esophagus and esophagogastric junction
    Knoedler, M.
    Kuhnt, T.
    Lordick, F.
    ONKOLOGE, 2014, 20 (12): : 1210 - +
  • [39] PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma
    Husstegge, Marlon
    Ngoc Anh Hoang
    Rebstock, Jakob
    Monecke, Astrid
    Gockel, Ines
    Weimann, Arved
    Schumacher, Guido
    Bechmann, Ingo
    Lordick, Florian
    Kallendrusch, Sonja
    Koerfer, Justus
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [40] Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction
    Hosoda K.
    Yamashita K.
    Katada N.
    Watanabe M.
    General Thoracic and Cardiovascular Surgery, 2015, 63 (10) : 549 - 556
12345